This episode explores the advancements in pharmaceutical research and the challenges faced by the industry. The conversation features Emma Walmsley, CEO of GSK, discussing the company's innovative drug and vaccine pipeline, including new technologies like antibody drug conjugates and oligonucleotides targeting diseases such as multiple myeloma and Hepatitis B. Against the backdrop of these scientific breakthroughs, the discussion pivots to the role of AI in accelerating drug development, with Walmsley highlighting the potential for faster, more precise outcomes in clinical trials. More significantly, the episode addresses the ongoing tension between drug pricing, accessibility, and the industry's social responsibility to reach a global population in need. For instance, Walmsley emphasizes GSK's commitment to access and its efforts to combat vaccine hesitancy through transparent communication and community engagement. In closing, Walmsley reflects on the importance of purpose, opportunity, and human connection as sources of energy in driving progress in the pharmaceutical field, highlighting the immense unmet needs in areas like neurodegeneration. This underscores the evolving landscape of pharmaceutical innovation and its impact on global health.
